• 제목/요약/키워드: COX-1, COX-2

검색결과 2,093건 처리시간 0.032초

Progression-Free Survival: An Important Prognostic Marker for Long-Term Survival of Small Cell Lung Cancer

  • Park, Myoung-Rin;Park, Yeon-Hee;Choi, Jae-Woo;Park, Dong-Il;Chung, Chae-Uk;Moon, Jae-Young;Park, Hee-Sun;Jung, Sung-Soo;Kim, Ju-Ock;Kim, Sun-Young;Lee, Jeong-Eun
    • Tuberculosis and Respiratory Diseases
    • /
    • 제76권5호
    • /
    • pp.218-225
    • /
    • 2014
  • Background: Small cell lung cancer (SCLC) is an extremely aggressive tumor with a poor clinical course. Although many efforts have been made to improve patients' survival rates, patients who survive longer than 2 years after chemotherapy are still very rare. We examined the baseline characteristics of patients with long-term survival rates in order to identify the prognostic factors for overall survivals. Methods: A total of 242 patients with cytologically or histologically diagnosed SCLC were enrolled into this study. The patients were categorized into long- and short-term survival groups by using a survival cut-off of 2 years after diagnosis. Cox's analyses were performed to identify the independent factors. Results: The mean patient age was 65.66 years, and 85.5% were males; among the patients, 61 of them (25.2%) survived longer than 2 years. In the multivariate analyses, CRP (hazard ratio [HR], 2.75; 95% confidence interval [CI], 1.25-6.06; p=0.012), TNM staging (HR, 3.29; 95% CI, 1.59-6.80; p=0.001), and progression-free survival (PFS) (HR, 11.14; 95% CI, 2.98-41.73; p<0.001) were independent prognostic markers for poor survival rates. Conclusion: In addition to other well-known prognostic factors, this study discovered relationships between the long-term survival rates and serum CRP levels, TNM staging, and PFS. In situations with unfavorable conditions, the PFS would be particularly helpful for managing SCLC patients.

자궁경부암의 방사선치료후 대장 및 직장합병증에 대한 분석 (Bowel Complication after Radiotherpy of Uterine Cervix Carcinoma)

  • 하성환;정웅기;김종훈
    • Radiation Oncology Journal
    • /
    • 제10권2호
    • /
    • pp.237-245
    • /
    • 1992
  • 1979년부터 1986년까지 자궁경부암으로 진단되어 외부방사선 및 강내 방사선 치료를 함께 받은 550명의 환자를 대상으로 직장 합병증과 방사선량에 대한 후향적 분석을 시행하였다. 전체 환자550명 중 468명은 근치적 목적으로 방사선 치료를 받았으며, 82명은 수술후에 추가적인 방사선 치료를 받았다. 이들 82명 중 43명은 수술절제연 양성으로, 31명은 원발질환의 재발로, 8명은 stump cancer로 방사선 치료를 받았다. Grade 2와 3를 포함하는 직장 합병증의 발생률은 5년에 $6.7였다. 합병증이 생긴 환자군의 직장에 조사된 방사선량은 $7424{\pm}834$ cGy이었으며, 이는 합병증이 발생하지 않은 환자군의 $6946{\pm}717$ cGy보다 많았고 통계학적 유의성이 있었다(p<0.05) 직장합병증의 정도에 따른 방사선량의 차이는 통계학적 유의성이 없었다(p>0.05). 전체 합병증의 발생률은 직장에 조사된 방사선량에 따라 증가하였는데, 6,500 cGy 이하에서는 5년 합병증 발생률이 15.6이었으며 8,000 cGy 이 상 조사된 환자군에서는 71.2이었다. 직장 합병증에 영향을 줄 수 있는 요인들을 Cox의 방법에 의해 다변량분석한 결과 당뇨가 있는 경우 합병증 발생률이 증가하였으며, 강내 방사선치료는 한번 시행한 경우보다 두번 시행한 환자군에서 합병증 발생률이 더 적었다. 또한 자궁의 후방만곡은 ovoid의 크기와 함께 분석된 경우에 통계적으로 중요한 의미를 나타내었고, ovoid의 크기는 이번 분석에서 합병증 발생에 가장 중요한 인자로 나타났다. 직장에 조사된 방사선량도 중요한 요소로서 방사선량이 많아질수록 합병증 발생률은 증가하였다(p<0.05). TDF와 CRE단위로 분석하였으며 선량과 합병증의 관계는 cGy 단위의 결과와 같았다.

  • PDF

유기농 콩 추출물의 항염증 및 항알레르기 효과 (Anti-inflammatory and Anti-allergic Effect of Extractsfrom Organic Soybean)

  • 정은경;서은혜;박준호;심혜림;김경희;이병용
    • 한국유기농업학회지
    • /
    • 제19권2호
    • /
    • pp.245-253
    • /
    • 2011
  • 유기농재배 콩을 다양한 용매에서 추출하여 그 추출물에 대한 항산화 효과, 항염증 효과, 대식세포의 세포사멸 보호 효과, 그리고 알레르기 저해효과를 비교하였다. DPPH 법과 SOD 효소의 활성 측정으로 항산화 능력을 평가하였으며, 항염증 효과는 LPS로 유도시킨 Raw 264.7 세포주에서 염증 매개 단백질인 Cox-2와 iNOS의 발현량을 Western blotting으로 조사하여 분석하였다. 또한 대식세포 보호 효과를 세포사멸 조절 단백질인 Bcl-xl의 발현량조사로 평가하였고, 1mM $H_2O_2$ 처리로 유도되는 세포사멸의 보호효과를 세포 수 측정법으로 조사하였다. 항알레르기 효과는 흰쥐의 비만세포인 RBL-2H3 세포주를 사용하여 IgE로 매개되는 비만세포의 탈과립화를 OPT assay로 측정하여 분석하였다. 그 결과, 유기 재배 콩의 다양한 추출물에서 항산화, 세포사멸 보호, 항염증 효과를 나타내었다. 특히 유기농 콩의 열수 추출물은 LPS로 유도시킨 염증반응을 효과적으로 억제하는 것으로 나타났다. 그러나 항알레르기 효과는 모든 추출물에서 히스타민 유리량이 약간 감소하는 것으로 나타나 유기농 콩의 특별한 효과를 확인할 수 없었다. 콩에는 많은 유용한 생리활성물질 뿐 만 아니라 알레르기 유발 물질도 존재하는 것으로 알려져 있지만 조추출물 상태에서는 특이적인 알레르기 유발보다 오히려 항알레르기 효과가 나타났다. 결론적으로, 만성 염증 및 천식, 그리고 아토피피부염과 같은 염증관련 질환에는 유기 재배된 콩이 좋은 억제 효과를 가지고 있다고 판단된다.

Prognostic Significance of Overexpression of EZH2 and H3k27me3 Proteins in Gastric Cancer

  • He, Long-Jun;Cai, Mu-Yan;Xu, Guo-Liang;Li, Jian-Jun;Weng, Zi-Jin;Xu, Da-Zhi;Luo, Guang-Yu;Zhu, Sen-Lin;Xie, Dan
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제13권7호
    • /
    • pp.3173-3178
    • /
    • 2012
  • The enhancer of zeste homolog 2 (EZH2) methyl transferase and histone 3 lysine 27 (H3K27me3) protein can repress gene transcription, and their aberrant expression has been observed in various human cancers. This study determined their expression levels in gastric cancer tissues with reference to clinicopathological features and patient survival. We collected 117 gastric cancer and corresponding normal tissues for immunohistochemistry analysis. In gastric cancers, 82/117 (70.1%) were positive for EZH2 and 66/117 (56.4%) for H3K27me3 proteins in contrast to only 5.41% and 7.25% of normal gastric mucosa specimens, respectively. Kaplan-Meier survival data showed the average overall and disease-free survival of EZH2 high expression patients was 25.2 and 20.2 months, respectively, shorter than that with EZH2 low expression (40.5 and 35.9 months). The average overall survival and disease-free survival of high H3K27me3 expression patients was 23.4 and 17.4 months, shorter than without H3K27me3 expression (37.6 and 34.5 months). The average overall survival and disease-free survival of patients with both EZH2 and H3K27me3 expression was 18.8 and 12.9 months, respectively, shorter than that with either alone (34.7 and 31.2 months) or with low levels of both (43.9 and 39.9 months). Multivariate Cox regression analysis showed that H3K27me3 and EZH2 expression, tumor size differentiation and clinical stage were all independent prognostic factors for predicting patient survival. This study demonstrated that detection of both EZH2 and H3K27me3 proteins can predict poor survival of gastric cancer patients, superior to single protein detection. In addition, H3K27me3 and EZH2 protein expression could predict lymph node metastasis.

Partial versus Radical Nephrectomy for T1-T2 Renal Cell Carcinoma in Patients with Chronic Kidney Disease Stage III: a Multiinstitutional Analysis of Kidney Function and Survival Rate

  • Chung, Jae-Seung;Son, Nak Hoon;Lee, Sang Eun;Hong, Sung Kyu;Jeong, Chang Wook;Kwak, Cheol;Kim, Hyeon Hoe;Hong, Sung Hoo;Kim, Yong June;Kang, Seok Ho;Chung, Jinsoo;Kwon, Tae Gyun;Hwang, Eu Chang;Byun, Seok-Soo
    • Journal of Korean Medical Science
    • /
    • 제33권43호
    • /
    • pp.277.1-277.10
    • /
    • 2018
  • Background: To examine survival rates and renal function after partial nephrectomy (PN) and radical nephrectomy (RN) in patients with chronic kidney disease (CKD). Methods: We studied 4,332 patients who underwent PN or RN for pathological T1a-T2N0M0 renal cell carcinoma from 1988 to 2014. Patients were divided into two subgroups of CKD stage I-II and stage III. Kidney function, and survival outcomes were compared between groups. Results: We included 1,756 patients with CKD I-II and 276 patients with CKD III in the final pair-matched analysis. Kidney function was significantly better preserved in the PN than in the RN group among all patients. However, the beneficial effect of PN on kidney function gradually disappeared over time in CKD III patients. The 5-year overall survival (OS) rates after PN and RN differed in patients with CKD I-II disease (99.4% vs. 96.5%, respectively, P = 0.015). The 5-year OS rates after surgery were not affected by mode of nephrectomy in CKD III patients (97.8% vs. 93.5%, P = 0.103). The 5-year cancer-specific survival rates did not differ between treatment groups in all CKD stage. Cox hazard analysis showed that the operative method was a significant factor for OS in CKD I-II patients (hazard ratio [HR], 0.320; confidence interval [CI], 0.122-0.840; P = 0.021). However, PN was not beneficial in terms of OS in CKD III patients (HR, 0.395; CI, 0.086-1.172; P = 0.117). Conclusion: PN is associated with a higher OS rate and better kidney function in patients with preoperative CKD stage I and II, but not in those with CKD stage III.

C-reactive Protein Concentration Is Associated With a Higher Risk of Mortality in a Rural Korean Population

  • Lee, Jung Hyun;Yeom, Hyungseon;Kim, Hyeon Chang;Suh, Il;Kim, Mi Kyung;Shin, Min-Ho;Shin, Dong Hoon;Koh, Sang-Baek;Ahn, Song Vogue;Lee, Tae-Yong;Ryu, So Yeon;Song, Jae-Sok;Choe, Hong-Soon;Lee, Young-Hoon;Choi, Bo Youl
    • Journal of Preventive Medicine and Public Health
    • /
    • 제49권5호
    • /
    • pp.275-287
    • /
    • 2016
  • Objectives: C-reactive protein (CRP), an inflammatory biomarker, has been widely used as a preclinical marker predictive of morbidity and mortality. Although many studies have reported a positive association between CRP and mortality, uncertainty still remains about this association in various populations, especially in rural Korea. Methods: A total of 23 233 middle-aged participants (8862 men and 14 371 women) who were free from cardiovascular disease, cancer, and acute inflammation (defined by a CRP level ${\geq}10mg/L$) were drawn from 11 rural communities in Korea between 2005 and 2011. Blood CRP concentration was analyzed as a categorical variable (low: 0.0-0.9 mg/L; intermediate: 1.0-3.0 mg/L; high: 3.1-9.9 mg/L) as well as a continuous variable. Each participant's vital status through December 2013 was confirmed by death statistics from the National Statistical Office. Cox proportional hazard models were used to assess the independent association between CRP and mortality after adjusting for other risk factors. Results: The total quantity of observed person-years was 57 975 for men and 95 146 for women, and the number of deaths was 649 among men and 367 among women. Compared to the low-CRP group, the adjusted hazard ratio for all-cause mortality of the intermediate group was 1.17 (95% confidence interval [CI], 0.98 to 1.40) for men and 1.27 (95% CI, 1.01 to 1.61) for women, and the corresponding values for the high-CRP group were 1.98 (95% CI, 1.61 to 2.42) for men and 1.41 (95% CI, 1.03 to 1.95) for women. Similar trends were found for CRP evaluated as a continuous variable and for cardiovascular mortality. Conclusions: Higher CRP concentrations were associated with higher mortality in a rural Korean population, and this association was more prominent in men than in women.

유기농 대두 추출물의 항염증 및 항알레르기 효과 (Anti-inflammatory and anti-allergic effect of soybean extracts produced by organic cultivation)

  • 정은경;서은혜;박준호;김영남;김경희;이병용
    • 한국유기농업학회:학술대회논문집
    • /
    • 한국유기농학회 2009년도 하반기 학술대회
    • /
    • pp.103-113
    • /
    • 2009
  • 유기농 및 일반재배 대두를 다양한 용매에서 추출하여 그 추출물에 대한 항산화 효과, 항염증 효과, 대식세포의 세포사멸 보호 효과, 그리고 알레르기 저해효과를 비교하였다. DPPH 법과 SOD 효소의 활성 측정으로 항산화 능력을 평가하였으며, 항염증 효과는 LPS로 유도시킨 Raw 264.7 세포주에서 염증 매개 단백질인 Cox-2와 iNOS의 발현량을 western blotting으로 조사하여 분석하였다. 또한 대식세포 보호 효과를 세포사멸 조절 단백질인 Bcl-xl의 발현량 조사로 평가하였고, 1 mM $H_2O_2$ 처리로 유도되는 세포사멸의 보호효과를 세포 수 측정법으로 조사하였다. 항알레르기 효과는 흰쥐의 비만세포인 RBL-2H3 세포주를 사용하여 IgE로 매개되는 비만세포의 탈과립화를 OPT assay로 측정하여 분석하였다. 그 결과, 일반 재배보다 유기 재배 대두 추출물이 더 좋은 항산화, 세포사멸 보호, 항염증 효과를 나타내었다. 특히 유기농 대두의 열수 추출물은 LPS로 유도시킨 염증반응을 효과적으로 억제하는 것으로 나타났다. 그러나 항알레르기 효과는 모든 추출물에서 히스타민 유리량이 약간 감소하는 것으로 나타나 유기농과 일반재배의 차이를 확인할 수 없었다. 대두에는 많은 유용한 생리활성물질 뿐 만 아니라 알레르기 유발 물질도 존재하는 것으로 알려져 있지만 조추출물 상태에서는 특이적인 알레르기 유발보다 오히려 항알레르기 효과가 나타났다. 결론적으로, 만성 염증 및 천식, 그리고 아토피피부염과 같은 염증관련 질환에는 유기재배된 대두가 일반 대두보다 좋은 억제 효과를 가지고 있다고 판단된다.

  • PDF

N과 AlN 시트에 다양한 기체(COx, NOx, SOx)의 흡착에 관한 이론 연구 (Theoretical Investigation for the Adsorption of Various Gases (COx, NOx, SOx) on the BN and AlN Sheets)

  • 김성현;김백진;신창호;김승준
    • 대한화학회지
    • /
    • 제61권1호
    • /
    • pp.16-24
    • /
    • 2017
  • 본 연구는 그래핀과 유사한 2차원 붕소-질소(BN)와 알루미늄-질소(AlN) 시트에 여러 대기 유해 가스($CO_x$, $NO_x$, $SO_x$)가 흡착될 때의 구조적 특징과 결합에너지를 밀도 범함수 이론(DFT)과 MP2 방법을 사용하여 연구하였다. 분자 구조는 $B3LYP/6-31G^{**}$$CAM-B3LYP/6-31G^{**}$이론 수준에서 최적화하고, 진동 주파수를 계산하여 열역학적으로 가장 안정한 분자 구조를 확인하였다. 결합에너지는 $MP2/6-31G^{**}$ 이론 수준에서 한 점(single point) 에너지를 계산하고, 영점 진동에너지(ZPVE)와 바탕집합 중첩에러(BSSE)를 모두 보정하였다. BN 시트에 가스의 흡착은 모두 물리흡착으로 예측되었으며, AlN 시트에 대한 가스 흡착은 $CO_x$$NO_x$에 대해서는 물리흡착이 그리고 $SO_x$에 대해서는 화학 흡착이 일어날 것으로 예측되었다.

The Prognostic Value of 18F-Fluorodeoxyglucose PET/CT in the Initial Assessment of Primary Tracheal Malignant Tumor: A Retrospective Study

  • Dan Shao;Qiang Gao;You Cheng;Dong-Yang Du;Si-Yun Wang;Shu-Xia Wang
    • Korean Journal of Radiology
    • /
    • 제22권3호
    • /
    • pp.425-434
    • /
    • 2021
  • Objective: To investigate the potential value of 18F-fluorodeoxyglucose (FDG) PET/CT in predicting the survival of patients with primary tracheal malignant tumors. Materials and Methods: An analysis of FDG PET/CT findings in 37 primary tracheal malignant tumor patients with a median follow-up period of 43.2 months (range, 10.8-143.2 months) was performed. Cox proportional hazards regression analyses were used to assess the associations between quantitative 18F-FDG PET/CT parameters, other clinic-pathological factors, and overall survival (OS). A risk prognosis model was established according to the independent prognostic factors identified on multivariate analysis. A survival curve determined by the Kaplan-Meier method was used to assess whether the prognosis prediction model could effectively stratify patients with different risks factors. Results: The median survival time of the 37 patients with tracheal tumors was 38.0 months, with a 95% confidence interval of 10.8 to 65.2 months. The 3-year, 5-year and 10-year survival rate were 54.1%, 43.2%, and 16.2%, respectively. The metabolic tumor volume (MTV), total lesion glycolysis (TLG), maximum standardized uptake value, age, pathological type, extension categories, and lymph node stage were included in multivariate analyses. Multivariate analysis showed MTV (p = 0.011), TLG (p = 0.020), pathological type (p = 0.037), and extension categories (p = 0.038) were independent prognostic factors for OS. Additionally, assessment of the survival curve using the Kaplan-Meier method showed that our prognosis prediction model can effectively stratify patients with different risks factors (p < 0.001). Conclusion: This study shows that 18F-FDG PET/CT can predict the survival of patients with primary tracheal malignant tumors. Patients with an MTV > 5.19, a TLG > 16.94 on PET/CT scans, squamous cell carcinoma, and non-E1 were more likely to have a reduced OS.

Impact of Treatment Type on Overall Survival in Elderly Brazilian Women with Breast Cancer

  • Bello, Marcelo Adeodato;de Menezes, Raquel Ferreira;de Sousa Silva, Brunna;da Silva, Rafael de Carvalho;Cavalcanti, Rousiane Silva;da Costa Moraes, Thayane de Fatima;Tonellotto, Fabiana;de Aguiar, Suzana Sales;Martucci, Renata Brum;Bergmann, Anke;Thuler, Luiz Claudio Santos
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제17권10호
    • /
    • pp.4769-4774
    • /
    • 2016
  • Objective: To analyze the survival of elderly patients with breast cancer according to the type of treatment used. Methods: A cohort study of women aged 80 or over with breast cancer registered with the Brazilian National Cancer Institute (Instituto Nacional do $C{\hat{a}}ncer$ - INCA) between 2008 and 2009 was conducted. Prognosis was analyzed according to the cancer treatment performed: surgery, radiotherapy, or hormone therapy. Analysis of the overall 5-year survival rate was performed using the Kaplan - Meier method, and comparisons of curves were undertaken using the log-rank test. For multiple regression analysis, Cox regression was used, adjusting for age and clinical stage, considering values of p < 0.05 as significant. Data were all analyzed using the statistical package SPSS version 20. Results: 70 women with a mean age of $84.0{\pm}3.7years$ at diagnosis participated in the study. The median follow-up time was 37.1 months (range 0.5-75.5), and 31 deaths (44.3%) occurred during this time. The median survival time was 51.2 months (95% CI, 44.9-57.4), higher in those who underwent surgery (p = 0.012) and those who had hormone therapy (p=0.001). Treatment with surgery reduced the risk of death by 61.7% (HR 0.3; 95% CI, 0.1-0.6; p = 0.001) when adjusted for clinical stage and age at diagnosis. However, there was no significant benefit from radiotherapy (HR 1.2; 95% CI, 0.5-2.5; p = 0.694). Conclusion: Treatment with surgery and hormone therapy increased the survival of our Brazilian patients with breast cancer aged 80 or over.